Table 2 Univariable and multivariable models for predicting U-TXM (based on log-transformed values). Panel A at registration and panel B at the end of the run-in period.

From: Thromboxane biosynthesis in cancer patients and its inhibition by aspirin: a sub-study of the Add-Aspirin trial

(A)
Baseline characteristic	Univariable models			Multivariable model^d
	Estimate	(95% CI)	P value	Estimate	(95% CI)	P value
Tumour type
Breast	Reference	–
Colorectal	0.28	(0.16, 0.40)	<0.001	0.35	(0.22, 0.48)	<0.001
Gastro-oesophageal	0.73	(0.54, 0.92)	<0.001	0.71	(0.51, 0.92)	<0.001
Prostate	−0.01	(−0.13, 0.11)	0.856	0.08	(−0.12, 0.14)	0.904
Gender
Male	Reference	–
Female	−0.11	(−0.21, −0.02)	0.023
Age at registration (years)
<50 years	Reference	−
50–59 years	0.03	(−0.12, 0.18)	0.656
60–69 years	0.02	(−0.13, 0.16)	0.836
70 years or over	0.15	(−0.01, 0.31)	0.063
BMI
BMI < 25	Reference	–
BMI 25–29.9	−0.03	(−0.15, 0.09)	0.634
BMI 30–34.9	−0.11	(−0.25, 0.04)	0.154
BMI 35 or over	0.14	(−0.04, 0.32)	0.116	0.22	(0.06, 0.39)	0.008
Smoking status
Never smoked	Reference	–
Previous smoker	0.13	(0.03, 0.23)	0.011
Current smoker	0.46	(0.24, 0.68)	<0.001
Diabetic
Not diabetic	Reference	–
Diabetic	0.09	(−0.13, 0.31)	0.414
Receiving BP treatment
No BP treatment	Reference	–
On BP treatment	−0.02	(−0.14, 0.09)	0.688
Statin use in last week
No recent statin use	Reference	–
Statins within last week	−0.06	(−0.19, 0.08)	0.428
Neutrophils (10⁹/L)
Neutrophils <5.0 × 10⁹/L	Reference	–
Neutrophils ≥5.0 × 10⁹/L	0.31	(0.15, 0.46)	<0.001	0.25	(0.09, 0.41)	0.003
Total WCC (10⁹/L)
Total WCC < 8.0 × 10⁹/L	Reference	–
Total WCC ≥ 8.0 × 10⁹/L	0.42	(0.24, 0.60)	<0.001
Platelet count (10⁹/L)
Platelet count <350 × 10⁹/L	Reference	–
Platelet count ≥350 × 10⁹/L	0.32	(0.10, 0.54)	0.005	0.26	(0.03, 0.50)	0.027
Raised LDL, total cholesterol or non-HDL
Normal cholesterol levels	Reference	–
Raised LDL, total cholesterol or non-HDL^a	−0.02	(−0.13, 0.08)	0.647
CRP result (categorised)
CRP ≤ 5	Reference	–
CRP > 5	0.18	(0.03, 0.33)	0.017	0.16	(0.003, 0.31)	0.046
Higher-risk disease
Lower-risk disease	Reference	–
Higher-risk disease^b	0.10	(0.00, 0.20)	0.049
Primary treatment details
Surgery, no adjuvant chemo	Reference	–
Surgery and adjuvant chemo	0.21	(0.10, 0.32)	<0.001
Radical RT or CRT	−0.05	(−0.20, 0.11)	0.538
Timing of surgery/primary treatment
6–12 weeks since surgery^c	Reference	–
>12 weeks since surgery	0.11	(−0.01, 0.24)	0.074
Radical RT or CRT	−0.09	(−0.26, 0.08)	0.282

(B)
Baseline characteristic	Univariable models^d			Multivariable model^d
	Estimate	(95% CI)	P value	Estimate	(95% CI)	P value
Tumour type
Breast	Reference	–
Colorectal	0.11	(−0.02, 0.24)	0.086
Gastro-oesophageal	0.11	(−0.10, 0.32)	0.306
Prostate	0.00	(−0.12, 0.12)	0.975
Gender
Male	Reference	–
Female	−0.07	(−0.17, 0.03)	0.150
Age at registration (years)
<50 years	Reference	–
50–59 years	0.03	(−0.12, 0.18)	0.663
60–69 years	−0.01	(−0.15, 0.13)	0.915
70 years or over	0.13	(−0.03, 0.28)	0.120	0.13	(0.003, 0.27)	0.045
BMI
BMI < 25	Reference	–
BMI 25–29.9	−0.09	(−0.21, 0.03)	0.162
BMI 30–34.9	0.03	(−0.11, 0.18)	0.642
BMI 35 or over	0.05	(−0.13, 0.22)	0.604
Smoking status
Never smoked	Reference	–
Previous smoker	0.12	(0.02, 0.22)	0.024	0.16	(0.05, 0.26)	0.005
Current smoker	0.22	(−0.01, 0.44)	0.064	0.31	(0.04, 0.57)	0.025
Diabetic
Not diabetic	Reference	–
Diabetic	0.30	(0.08, 0.52)	0.008	0.31	(0.06, 0.56)	0.014
Receiving BP treatment
No BP treatment	Reference	–
On BP treatment	0.08	(−0.03, 0.20)	0.156
Statin use in last week
No recent statin use	Reference	–
Statins within last week	0.11	(−0.03, 0.24)	0.134
Neutrophils (10⁹/L)
Neutrophils <5.0 × 10⁹/L	Reference	–
Neutrophils ≥5.0 × 10⁹/L	0.21	(0.05, 0.37)	0.011	0.23	(0.06, 0.40)	0.008
Total WCC (10⁹/L)
Total WCC < 8.0 × 10⁹/L	Reference	–
Total WCC ≥ 8.0 × 10⁹/L	0.18	(−0.01, 0.37)	0.067
Platelet count (10⁹/L)
Platelet count <350 × 10⁹/L	Reference	–
Platelet count ≥350 × 10⁹/L	−0.04	(−0.27, 0.19)	0.748
Raised LDL, total cholesterol or non-HDL
Normal cholesterol levels	Reference	–
Raised LDL, total cholesterol or non-HDL^a	−0.04	(−0.14, 0.07)	0.457
CRP result (categorised)
CRP ≤ 5	Reference	–
CRP > 5	0.22	(0.06, 0.37)	0.006
Higher-risk disease
Lower-risk disease	Reference	–
Higher-risk disease^b	−0.09	(−0.19, 0.01)	0.083
Primary treatment details
Surgery, no adjuvant chemo	Reference	–
Surgery and adjuvant chemo	0.02	(−0.09, 0.13)	0.664
Radical RT or CRT	0.04	(−0.11, 0.20)	0.577
Timing of surgery/primary treatment
6–12 weeks since surgery^c	Reference	–
>12 weeks since surgery	0.06	(−0.07, 0.18)	0.380
Radical RT or CRT	0.07	(−0.10, 0.24)	0.418

Univariable and multivariable models for predicting U-TXM (based on log-transformed values of U-TXM) at baseline (trial registration) (Panel A) and at the end run-in period (Panel B).
^aLDL > 3, total cholesterol >5 or non-HDL > 4; note that participants with at least one of LDL, HDL and total cholesterol measured and in the normal range (and no raised measurements) are included in the normal group even if other measurements are missing.
^bBreast Stage III; colorectal Stage III or IV; gastro-oesophageal Stage IIB or III; prostate high risk according to D’Amico classification.
^cTiming of surgery was not considered in the multivariate model due to being confounded with the primary treatment variable and since it was non-significant in the univariate model.
^dThe final multivariable model at registration is based on n = 552 observations (some observations are not included due to missing covariate information—see earlier table); R² = 16.8%. At the end of the run-in period the final multivariable model is based on n = 402 observations R² = 32.3%. All models are adjusted for (log-transformed) baseline U-TXM.

Back to article page

Table 2 Univariable and multivariable models for predicting U-TXM (based on log-transformed values). Panel A at registration and panel B at the end of the run-in period.

Search

Quick links